Good morning, it's Jack here with Tuesday's SCVR. I'm interested in quite an exciting announcement from Novacyt SA (LON:NCYT) so without further ado let's dive in! Novacyt (LON:NCYT) Share price: 565pp (+20.9%) No. shares: 70.6m Market cap: £331.4m (I hold) Launch of COVID-19 antibody test and New UK DHSC Contract. I’ve been wary of buying stock in companies that attach their name to the ongoing COVID pandemic but with Novacyt Sa (LON:NCYT) it seems that the transformational trading figures are already in the bag and the market is perhaps slow to acknowledge that. This is an international specialist in clinical diagnostics whose business now sees unprecedented levels of demand. The group’s recent half year update was extremely strong and the outlook for the rest of the group’s financial year is impressive. Jumping back to that statement: H1 2020 sales of €72.4m and EBITDA was €49.4m, resulting from the sale of the Company's market leading PCR COVID-19 test, andVisibility of orders for the Company's COVID-19 product portfolio suggests H2 2020 performance on track to exceed that of H1...
